Press release
Deadline in Lawsuit for Investors in Cabaletta Bio, Inc. (NASDAQ: CABA) coming up on April 29, 2022
A Deadline is coming up on April 29, 2022 in the lawsuit for certain investors in Cabaletta Bio, Inc. (NASDAQ: CABA).
Investors who purchased shares of Cabaletta Bio, Inc. (NASDAQ: CABA) have certain options and there are strict and short deadlines running. Deadline: April 29, 2022 . NASDAQ: CABA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA) common shares between October 24, 2019 and December 13, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 24, 2019 and December 13, 2021, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion, that accordingly, DSG3-CAART was not as effective as the Company had represented to investors, that therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Cabaletta Bio, Inc. (NASDAQ: CABA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline in Lawsuit for Investors in Cabaletta Bio, Inc. (NASDAQ: CABA) coming up on April 29, 2022 here
News-ID: 2612171 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Cabaletta
Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hof …
DelveInsight's, "Lupus Nephritis - Pipeline Insight, 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Lupus Nephritis pipeline involves over 35…
Pemphigus Vulgaris Market Growth Projections 2024-2034: DelveInsight Analysis | …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Myasthenia Gravis Clinical Trial Analysis, 2024 Updates | Latest FDA, EMA, and P …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Myasthenia Gravis Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Ap …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Myasthenia Gravis Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Ap …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 20+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Myasthenia Gravis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market.
The Myasthenia…
Investigation announced for Investors in shares of Cabaletta Bio, Inc. (NASDAQ: …
An investigation was announced over possible breaches of fiduciary duties by certain directors and officers of Cabaletta Bio, Inc.
Investors who are current long term investors in Cabaletta Bio, Inc. (NASDAQ: CABA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: CABA stocks follows a lawsuit filed against Cabaletta Bio,…
